CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

Ähnliche Einträge

• Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
  von: Jian Wang, et al.
  Veröffentlicht: (2024)
• Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
  von: Yen‐Chun Liu, et al.
  Veröffentlicht: (2024)
• Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
  von: Ying‐Nan Tsai, et al.
  Veröffentlicht: (2026)
• Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
  von: Hyeyeon Hong, et al.
  Veröffentlicht: (2024)
• Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
  von: Yuxin Chen, et al.
  Veröffentlicht: (2024)